Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.

Antonopoulos M, VAN Gool SW, Dionysiou D, Graf N, Stamatakos G.

Anticancer Res. 2019 Apr;39(4):2043-2051. doi: 10.21873/anticanres.13315.

PMID:
30952748
2.

Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group.

Rutkowski S, Modena P, Williamson D, Kerl K, Nysom K, Pizer B, Bartels U, Puget S, Doz F, Michalski A, von Hoff K, Chevignard M, Avula S, Murray MJ, Schönberger S, Czech T, Schouten-van Meeteren AYN, Kordes U, Kramm CM, van Vuurden DG, Hulleman E, Janssens GO, Solanki GA, van Veelen MC, Thomale U, Schuhmann MU, Jones C, Giangaspero F, Figarella-Branger D, Pietsch T, Clifford SC, Pfister SM, Van Gool SW.

Lancet Oncol. 2018 Aug;19(8):e419-e428. doi: 10.1016/S1470-2045(18)30364-4. Review.

PMID:
30102236
3.

Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.

Belmans J, Van Woensel M, Creyns B, Dejaegher J, Bullens DM, Van Gool SW.

Sci Rep. 2017 Oct 24;7(1):13902. doi: 10.1038/s41598-017-12584-0.

4.

Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade.

Dejaegher J, Verschuere T, Vercalsteren E, Boon L, Cremer J, Sciot R, Van Gool SW, De Vleeschouwer S.

Int J Cancer. 2017 Nov 1;141(9):1891-1900. doi: 10.1002/ijc.30877. Epub 2017 Jul 19.

5.

Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.

Van Woensel M, Mathivet T, Wauthoz N, Rosière R, Garg AD, Agostinis P, Mathieu V, Kiss R, Lefranc F, Boon L, Belmans J, Van Gool SW, Gerhardt H, Amighi K, De Vleeschouwer S.

Sci Rep. 2017 Apr 27;7(1):1217. doi: 10.1038/s41598-017-01279-1.

6.

Clinical-Grade Human Multipotent Adult Progenitor Cells Block CD8+ Cytotoxic T Lymphocytes.

Plessers J, Dekimpe E, Van Woensel M, Roobrouck VD, Bullens DM, Pinxteren J, Verfaillie CM, Van Gool SW.

Stem Cells Transl Med. 2016 Dec;5(12):1607-1619. Epub 2016 Jul 27.

7.

Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group.

van Gool SW, Holm S, Rachor J, Adamson L, Technau A, Maass E, Frühwald MC, Schlegel PG, Eyrich M.

Cytotherapy. 2016 Sep;18(9):1178-86. doi: 10.1016/j.jcyt.2016.06.004. Epub 2016 Jul 12.

PMID:
27421737
8.

mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70).

Coosemans A, Tuyaerts S, Morias K, Corthals J, Heirman C, Thielemans K, Van Gool SW, Vergote I, Amant F.

Methods Mol Biol. 2016;1428:277-83. doi: 10.1007/978-1-4939-3625-0_18.

PMID:
27236806
9.

Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma.

Vandenberk L, Garg AD, Verschuere T, Koks C, Belmans J, Beullens M, Agostinis P, De Vleeschouwer S, Van Gool SW.

Oncoimmunology. 2015 Sep 11;5(2):e1083669. eCollection 2016 Feb.

10.

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma.

Garg AD, Vandenberk L, Koks C, Verschuere T, Boon L, Van Gool SW, Agostinis P.

Sci Transl Med. 2016 Mar 2;8(328):328ra27. doi: 10.1126/scitranslmed.aae0105.

PMID:
26936504
11.

Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.

Van Woensel M, Wauthoz N, Rosière R, Mathieu V, Kiss R, Lefranc F, Steelant B, Dilissen E, Van Gool SW, Mathivet T, Gerhardt H, Amighi K, De Vleeschouwer S.

J Control Release. 2016 Apr 10;227:71-81. doi: 10.1016/j.jconrel.2016.02.032. Epub 2016 Feb 21.

PMID:
26902800
12.

Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.

Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW.

Front Immunol. 2016 Jan 14;6:663. doi: 10.3389/fimmu.2015.00663. eCollection 2015. Review.

13.

Diverse Cutaneous Presentations of Langerhans Cell Histiocytosis in Children: A Retrospective Cohort Study.

Morren MA, Vanden Broecke K, Vangeebergen L, Sillevis-Smitt JH, Van Den Berghe P, Hauben E, Jacobs S, Van Gool SW.

Pediatr Blood Cancer. 2016 Mar;63(3):486-92. doi: 10.1002/pbc.25834. Epub 2015 Nov 19.

PMID:
26586230
14.

Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients.

Ion-Margineanu A, Van Cauter S, Sima DM, Maes F, Van Gool SW, Sunaert S, Himmelreich U, Van Huffel S.

Biomed Res Int. 2015;2015:842923. doi: 10.1155/2015/842923. Epub 2015 Aug 27.

15.

Brain Tumor Immunotherapy: What have We Learned so Far?

Van Gool SW.

Front Oncol. 2015 Jun 17;5:98. doi: 10.3389/fonc.2015.00098. eCollection 2015. Review.

16.

CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity.

Vogel I, Kasran A, Cremer J, Kim YJ, Boon L, Van Gool SW, Ceuppens JL.

Eur J Immunol. 2015 Jun;45(6):1832-41. doi: 10.1002/eji.201445190. Epub 2015 Apr 3.

17.

Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?

Koks CA, De Vleeschouwer S, Graf N, Van Gool SW.

J Cancer. 2015 Jan 15;6(3):203-17. doi: 10.7150/jca.10640. eCollection 2015. Review.

18.

Dendritic cell immunotherapy in uterine cancer.

Coosemans A, Tuyaerts S, Vanderstraeten A, Vergote I, Amant F, Van Gool SW.

Hum Vaccin Immunother. 2014;10(7):1822-7. doi: 10.4161/hv.28716.

19.

Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.

Koks CA, Garg AD, Ehrhardt M, Riva M, Vandenberk L, Boon L, De Vleeschouwer S, Agostinis P, Graf N, Van Gool SW.

Int J Cancer. 2015 Mar 1;136(5):E313-25. doi: 10.1002/ijc.29202. Epub 2014 Sep 19.

20.

Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells.

Eyrich M, Schreiber SC, Rachor J, Krauss J, Pauwels F, Hain J, Wölfl M, Lutz MB, de Vleeschouwer S, Schlegel PG, Van Gool SW.

Cytotherapy. 2014 Jul;16(7):946-64. doi: 10.1016/j.jcyt.2014.02.017. Epub 2014 May 13.

PMID:
24831836

Supplemental Content

Loading ...
Support Center